CompletedNCT03901755
An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
Studying Hemophilia B
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swedish Orphan Biovitrum
- Principal Investigator
- Elena Santagostino, MDSwedish Orphan Biovitrum
- Intervention
- Alprolix(drug)
- Enrollment
- 151 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2024
Study locations (26)
- Swedish Orphan Biovitrum Research Site, Brno, Czechia
- Swedish Orphan Biovitrum Research Site, Prague, Czechia
- Swedish Orphan Biovitrum Research Site (Haemophilia Center Aghia Sophia Children's Hospital), Athens, Greece
- Swedish Orphan Biovitrum Research Site (Laikο General Hospital of Athens), Athens, Greece
- Swedish Orphan Biovitrum Research Site, Dublin, Ireland
- Swedish Orphan Biovitrum Research Site, Bari, Italy
- Swedish Orphan Biovitrum Research Site, Florence, Italy
- Swedish Orphan Biovitrum Research Site, Genova, Italy
- Swedish Orphan Biovitrum Research Site, Milan, Italy
- Swedish Orphan Biovitrum Research Site, Roma, Italy
- Swedish Orphan Biovitrum Research Site, Turin, Italy
- Swedish Orphan Biovitrum Research Site, Oslo, Norway
- Swedish Orphan Biovitrum Research Site (King Faisal Hospital adult), Riyadh, Saudi Arabia
- Swedish Orphan Biovitrum Research Site (King Faisal Hospital pediatric), Riyadh, Saudi Arabia
- Swedish Orphan Biovitrum Research Site (Hospital de Vall d'Hebrón), Barcelona, Spain
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03901755 on ClinicalTrials.govOther trials for Hemophilia B
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07285460A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BSanofi
- RECRUITINGPHASE3NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BCSL Behring
- RECRUITINGPHASE1, PHASE2NCT06611436BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia BBe Biopharma
- ACTIVE NOT RECRUITINGPHASE3NCT06569108Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT06003387Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)CSL Behring
- RECRUITINGNCT06008938An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BCSL Behring
- RECRUITINGNANCT05630651The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05709288Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldInstitute of Hematology & Blood Diseases Hospital, China